Compare Cytokinetics Inc (CYTK) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Vale SA — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while Vale SA trades at $13.47 (market cap $57.32B). The key difference: Vale SA is far larger — about 6.6× Cytokinetics Inc's market cap, and Vale SA pays a 8.87% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Vale SA for 109 Days on average.
| CYTK | VALE | |
|---|---|---|
Market Cap | $8.62B | $57.32B |
Volume | 2,594,626 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $87.26 | $17.82 |
52-Week Low | $54.76 | $10.75 |
Typical Hold Time | 19 Days | 109 Days |
Enterprise Value | $8.72B | $73.56B |
Dividend Yield | — | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
VALE trades at $13.61, down 3.34% amid broader market weakness in steel producers. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1-Q2 2026. Fundamentals reveal declining revenue from $43.8B in 2022 to $38.4B in 2025, with net income margin compressing to 5.11%. Analyst consensus remains mixed with 32% buy ratings but a $16.21 price target suggesting 19% upside potential.
VALE faces headwinds from iron ore price volatility and rising operational costs, though its base metals segment shows growth potential. The current valuation at P/E 26.84 appears stretched given earnings pressure. Key risks include Brazilian regulatory exposure and cyclical commodity dependence, while the dividend yield of approximately 2.9% provides some income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
